Surpass Elite血流导向装置治疗未破裂颅内动脉瘤的早期经验
单中心回顾性分析21例患者22个颅内动脉瘤应用Surpass Elite血流导向装置的治疗结果。24枚装置全部成功释放，技术成功率100%，无神经功能并发症及死亡，中位5个月影像随访完全闭塞率63.2%。研究提示该装置技术性能良好、安全性可接受，早期闭塞率与既往血流导向装置报告一致。
要点
- Surpass Elite血流导向装置技术成功率高，本组24枚均成功释放。
- 中位5个月随访完全闭塞率63.2%，充分闭塞率84.2%。
- 本组无术中、早期及迟发神经功能并发症，无颅内出血及死亡。
核心结论
- Surpass Elite血流导向装置在早期单中心经验中显示良好的技术性能、可接受的安全性及与既往血流导向装置一致的早期闭塞率。
研究设计与样本
- 研究类型为单中心回顾性分析，数据来源于前瞻性维护的数据库。
- 纳入2025年3月至2026年1月连续21例患者共22个颅内动脉瘤，均为囊性，其中3个为既往破裂动脉瘤。
- 共释放24枚Surpass Elite装置，平均每例患者1.1枚，5例（23.8%）经桡动脉入路操作。
诊断标准与关键数值
- 影像随访覆盖19/22个动脉瘤（86.4%），中位随访时间为5个月。
- 完全闭塞（OKM D级）为12/19个（63.2%），充分闭塞（OKM C-D级）为16/19个（84.2%）。
临床应用与阅片要点
- Surpass Elite具有超过150°的更高编织角和BioStealth表面修饰，释放时需关注其贴壁与打开特性。
- 本组中23.8%经桡动脉入路完成，提示该装置可适用于桡动脉路径。
- 中位5个月随访时完全闭塞率63.2%，报告时可参照此数据向临床提示短期随访闭塞预期。
局限性
- 本研究为小样本单中心队列，影像随访时间短，需更大规模多中心前瞻性研究并进行12至24个月影像随访以验证结论。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
PURPOSE: The Surpass Elite (Stryker Neurovascular) is the latest generation of the Surpass flow diverter (FD) platform, featuring a higher braid angle consistently exceeding 150°, the BioStealth surface modification, and an expanded size matrix. We report our early single-center experience with the Surpass Elite in the treatment of intracranial aneurysms.
METHODS: Retrospective analysis of a prospectively maintained database including 21 consecutive patients with 22 intracranial aneurysms treated with the Surpass Elite between March 2025 and January 2026 at a single high-volume neurointerventional center. We recorded and analyzed device deployment characteristics and imaging and clinical follow-up, as well as intraprocedural, early (< 30 days), and delayed (> 30 days) neurological complications.
RESULTS: Twenty-one patients (16 women, mean age 47 years) were treated for 22 aneurysms (3 previously ruptured, all saccular). Twenty-four devices were successfully deployed (mean of 1.1 devices per patient), with a 100% technical success rate. Five procedures (23.8%) were performed via radial access. No intraprocedural, early, or delayed neurological complications were observed. No intracranial hemorrhage or mortality occurred. All patients maintained a modified Rankin Scale score of 0 throughout follow-up. Imaging follow-up, available in 19/22 (86.4%) aneurysms (median 5 months), demonstrated complete occlusion (OKM grade D) in 12/19 (63.2%) and adequate occlusion (OKM grades C-D) < in 16/19 (84.2%).
CONCLUSION: Within the limits of a small single-center cohort and short imaging follow-up, our early experience with the Surpass Elite suggests favorable technical performance, an encouraging safety profile, and early occlusion rates consistent with previously reported flow diverters. Larger multicenter prospective studies with imaging follow-up extended to 12-24 months are warranted to confirm these preliminary findings.
引用
- Ajem, Kalsoum, Farhat, et al. Early experience with the Surpass Elite flow diverter for unruptured intracranial aneurysms. Neuroradiology. 2026. PMID: 42228146. doi:10.1007/s00234-026-04059-9
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。